Avian anti-NS1 IgY antibodies neutralize dengue virus infection and protect against lethal dengue virus challenge

Dengue is the most prevalent arboviral disease in humans and a continually increasing global public health burden. To date, there are no approved antiviral therapies against dengue virus (DENV) and the only licensed vaccine, Dengvaxia, is exclusively indicated for individuals with prior DENV infection. Endothelial hyperpermeability and vascular leak, pathogenic hallmarks of severe dengue disease, can be directly triggered by DENV non-structural protein 1 (NS1). As such, anti-NS1 antibodies can prevent NS1-triggered endothelial dysfunction in vitro and pathogenesis in vivo. Recently, goose-derived anti-DENV immunoglobulin Y (IgY) antibodies were shown to neutralize DENV and Zika virus (ZIKV) infection without adverse effects, such as antibody-dependent enhancement (ADE). In this study, we used egg yolks from DENV-immunized geese to purify IgY antibodies specific to DENV NS1 epitopes. We determined that 2 anti-NS1 IgY antibodies, NS1-1 and NS1-8, were capable of neutralizing DENV infection in vitro. In addition, these antibodies did not cross-react with the DENV Envelope (E) protein nor enhance DENV or ZIKV infection in vitro. Intriguingly, NS1-8, but not NS1-1, partially blocked NS1-induced endothelial dysfunction in vitro while neither antibody blocked binding of soluble NS1 to cells. Finally, prophylactic treatment of mice with NS1-8 conferred significant protection against lethal DENV challenge. Although further research is needed to define the mechanism of action of these antibodies, our findings highlight the potential of anti-NS1 IgY as a promising prophylactic approach against DENV infection.

Avian IgY antibodies recognize novel Dengue NS1 epitopes with the ability to neutralize Dengue 2 virus infection in vitro and in vivo

Dengue virus (DENV) causes 96 million infections worldwide resulting in 500,000 cases of Dengue Hemorrhagic Fever (DHF) and 22,000 deaths. The severity of DENV infection is greatly enhanced by antibody dependent enhancement (ADE); increased viral load due to increased monocyte opsonization by non-neutralizing low avidity Abs from a previous infection with a different DENV serotype or secondary flavivirus infection. We have previously demonstrated that polyclonal avian anti-DENV-2 IgY ameliorates DENV infection in mice without inducing ADE. The whole polyclonal anti-DENV-2 IgY preparation contained distinct populations of IgY that recognized numerous epitopes of the envelope, membrane, and non-structural (NS) DENV proteins. We report here that two purified pools of anti-DENV-2 IgY with specificity for two different regions of NS1 had a neutralization capacity equivalent to the whole polyclonal anti-DENV-2 IgY preparation in vitro. We assayed each pool of NS1-specific IgY for the potential to induce ADE and demonstrated that neither pool induced ADE when cells were treated with IgY and challenged with a flavivirus. To determine if these NS1 specific IgY achieved neutralization via reducing vascular leakage, we utilized a trans-endothelial electrical resistance (TEER) assay. Interestingly, treatment with DENV NS1-specific IgY did not reduced vascular leakage in our model system. Final to demonstrate the therapeutic potential of NS1 specific IgY we prophylactically treated IFNAR−/− mice with 150 μg of NS1 specific IgY and saw protective efficacy up to 100% in a lethal dengue challenge. We hypothesize that the neutralizing effect of the NS1 specific IgY is via the antibody disrupting the stability of the viral replication complex.

Zika Virus-Specific IgY Results Are Therapeutic Following a Lethal Zika Virus Challenge without Inducing Antibody-Dependent Enhancement

The Zika virus (ZIKV) is a newly emerged pathogen in the Western hemisphere. It was declared a global health emergency by the World Health Organization in 2016. There have been 223,477 confirmed cases, including 3720 congenital syndrome cases since 2015. ZIKV infection symptoms range from asymptomatic to Gullain⁻Barré syndrome and extensive neuropathology in infected fetuses. Passive and active vaccines have been unsuccessful in the protection from or the treatment of flaviviral infections due to antibody-dependent enhancement (ADE). ADE causes an increased viral load due to an increased monocyte opsonization by non-neutralizing, low-avidity antibodies from a previous dengue virus (DENV) infection or from a previous exposure to ZIKV. We have previously demonstrated that polyclonal avian IgY generated against whole-killed DENV-2 ameliorates DENV infection in mice while not inducing ADE. This is likely due to the inability of the Fc portion of IgY to bind to mammalian Fc receptors. We have shown here that ZIKV oligoclonal IgY is able to neutralize the virus in vitro and in IFNAR-/- mice. The concentration of ZIKV-specific IgY yielding 50% neutralization (NT50) was 25 µg/mL. The exposure of the ZIKV, prior to culture with ZIKV-specific IgY or 4G2 flavivirus-enveloped IgG, demonstrated that the ZIKV-specific IgY does not induce ADE. ZIKV IgY was protective in vivo when administered following a lethal ZIKV challenge in 3-week-old IFNAR-/- mice. We propose polyclonal ZIKV-specific IgY may provide a viable passive immunotherapy for a ZIKV infection without inducing ADE.

Necroptosis of infiltrated macrophages drives Yersinia pestis dispersal within buboes

When draining lymph nodes become infected by Yersinia pestis (Y. pestis), a massive influx of phagocytic cells occurs, resulting in distended and necrotic structures known as buboes. The bubonic stage of the Y. pestis life cycle precedes septicemia, which is facilitated by trafficking of infected mononuclear phagocytes through these buboes. However, how Y. pestis convert these immunocytes recruited by host to contain the pathogen into vehicles for bacterial dispersal and the role of immune cell death in this context are unknown. We show that the lymphatic spread requires Yersinia outer protein J (YopJ), which triggers death of infected macrophages by downregulating a suppressor of receptor-interacting protein kinase 1-mediated (RIPK1-mediated) cell death programs. The YopJ-triggered cell death was identified as necroptotic, which released intracellular bacteria, allowing them to infect new neighboring cell targets. Dying macrophages also produced chemotactic sphingosine 1-phosphate, enhancing cell-to-cell contact, further promoting infection. This necroptosis-driven expansion of infected macrophages in buboes maximized the number of bacteria-bearing macrophages reaching secondary lymph nodes, leading to sepsis. In support, necrostatins confined bacteria within macrophages and protected mice from lethal infection. These findings define necrotization of buboes as a mechanism for bacterial spread and a potential target for therapeutic intervention.

Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement

Dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are severe disease manifestations that can occur following sequential infection with different dengue virus serotypes (DENV1-4). At present, there are no licensed therapies to treat DENV-induced disease. DHF and DSS are thought to be mediated by serotype cross-reactive antibodies that facilitate antibody-dependent enhancement (ADE) by binding to viral antigens and then Fcγ receptors (FcγR) on target myeloid cells. Using genetically engineered DENV-specific antibodies, it has been shown that the interaction between the Fc portion of serotype cross-reactive antibodies and FcγR is required to induce ADE. Additionally, it was demonstrated that these antibodies were as neutralizing as their non-modified variants, were incapable of inducing ADE, and were therapeutic following a lethal, antibody-enhanced infection. Therefore, we hypothesized that avian IgY, which do not interact with mammalian FcγR, would provide a novel therapy for DENV-induced disease. We demonstrate here that goose-derived anti-DENV2 IgY neutralized DENV2 and did not induce ADE in vitro. Anti-DENV2 IgY was also protective in vivo when administered 24 hours following a lethal DENV2 infection. We were also able to demonstrate via epitope mapping that both full-length and alternatively spliced anti-DENV2 IgY recognized different epitopes, including epitopes that have not been previously identified. These observations provide evidence for the potential therapeutic applications of goose-derived anti-DENV2 IgY.

Dengue NS1-specific IgY antibodies neutralizes dengue infection without inducing antibody dependent enhancement

Dengue virus (DENV) is the most prevalent arbovirus with worldwide cases increasing from 2.2 to 3.2 million in the last 5 years. Symptoms of DENV infection range from a mild fever to extensive vasculature permeability resulting in hemorrhagic fever and shock. Passive and active vaccines have been unsuccessful in protecting from or treatment for DENV infection because of antibody dependent enhancement (ADE), increased viral load due to increased monocyte opsonization by non-neutralizing Abs from a different DENV serotype. We have previously demonstrated that polyclonal avian IgY generated against whole, killed DENV-2 ameliorates DENV infection in mice without ADE. The lack of ADE with therapeutic IgY supported our hypothesis that IgY may provide a viable treatment for DENV infection as mammalian Fc receptors are unable to bind to IgY. Here we isolated DENV epitope-specific IgY and test these purified IgY pools for their ability to neutralize DENV in vitro. Avian IgY specific for Non-Structural-1 (NS1) demonstrated neutralization capacity in vitro equal to the whole polyclonal DENV IgY preparation. DENV-NS3 specific IgY, on the other hand, did not demonstrate any neutralization of DENV in vitro. We propose that NS1-specific IgY may provide a viable oligoclonal treatment for DENV infection in humans without inducing ADE.

Purified type III secretion system needle proteins are novel TLR agonists that induce NF-κB signaling and stimulate NLRP3-dependent IL-1β production by innate cells in vitro

Purified type III secretion (T3S) system needle proteins from a number of Gram-negative bacteria have been identified as protective antigens as well as strong adjuvants in vivo. These proteins have been shown to act as TLR2 and TLR4 agonists, producing robust pro-inflammatory cytokine release in a MyD88-dependant manner from both human and mouse cells in vitro. Additionally, it has been established that TLR agonists alone can stimulate IL-1β through the NLRP3 inflammasome. Interestingly, we have demonstrated that T3S needle proteins induce NF-κB signaling downstream of both TLR2 and TLR4. Given the vaccine potential of T3S needle proteins, it is necessary to further understand the signaling mechanisms underlying their adjuvant properties. Here we characterized the innate signaling pathways engaged by T3S needle proteins. We show T3S needle proteins induce NF-κB signaling and pro-inflammatory cytokine release from mouse macrophages more strongly through TLR4 as compared to TLR2. Utilizing primary cells from inflammasome component knockout mice, we demonstrate that IL-1β secretion from T3S needle protein stimulated cells was dependent on the NLRP3 inflammasome, as well as caspase-1. Interestingly, pre-treatment with cytochalasin D reduced IL-1β secretion and resulted in the accumulation of intracellular pro-IL-1β after T3S needle protein stimulation; suggesting that internalization of T3S needle proteins is critical for inflammasome activation and IL-1β secretion. These findings further identify critical innate signaling pathways engaged by T3S needle proteins. T3S needle proteins have tremendous vaccine potential due to their ability to act as protective antigens and their innate immunity stimulating properties.

Humanized HLA-DQ8αβ transgenic mice treated with SEG/SEI superantigens exhibit long-term CD4+-mediated anti-tumor responses

SEG and SEI are primordial S. aureus superantigens (SAgs) notably unaccompanied by human neutralizing antibodies that have hampered the use of classic SAgs as cancer therapeutics. Here we show SEG/SEI presented from a HLA-DQ8αβ (HLA-DQA*0301 and HLA-DQB*0302) tg platform outperform C57BL/6 mice in achieving long term survival in vaccinated and established Lewis lung carcinoma (LLC) and B16-F10 melanoma. Vaccination of DQ8 tg mice with LLC or B16-F10 melanoma followed by SEG/SEI immunization and subsequent tumor challenge resulted in 100% and 83% survival for >150 days respectively, compared to a median survival of 14 days in unvaccinated DQ8 tg controls (p<0.001). Likewise, SEG/SEI treatment of established melanoma in DQ8 tg mice resulted in 100% survival for 70 days compared to a median survival of 20 days in untreated DQ8 tg controls. Similar vaccinations/challenges in C57BL/6 mice produced a median survival of 23–28 days. SEG/SEI-activated splenocytes from DQ8 tg mice displayed a TH-1/TH-17 cytokine phenotype with a threefold greater T cell proliferative and CD4+-mediated cytotoxicity responses, compared to C57BL/6 mice. These surprising data delineate a clear pathway to translation of an SEG/SEI-HLA-DQ8αβ tg platform for melanoma/lung cancer prophylaxis and treatment.

Expression and Purification of N-Terminally His-Tagged Recombinant Type III Secretion Proteins

The ability to express and purify recombinant needle proteins from the Type III Secretion System (T3SS) of many gram-negative bacteria has allowed us to develop novel experimental approaches, both in vitro and in vivo, to identify unique roles for T3SS in bacterial pathogenesis. In addition, these purified needle proteins have shown to be promising immunotherapies acting as both protective antigens and adjuvants, presumably due to their immune activating properties. Here, we describe the expression and purification of recombinant T3SS needle proteins.

Identification of the Targets of Type III Secretion System Inhibitors

A type III secretion system (T3SS) Inhibitor can be utilized for study in the research lab but also progressed into drug development. Since many pathogenic Gram-negative bacteria utilize this highly conserved system as a virulence factor, the prospect of the T3SS as a drug target is promising. To effectively move a T3SS inhibitor into the route of either research or pharmaceuticals an understanding of the target and mechanism of the inhibitor is required. Several methods can be utilized to identify the target. Included here is the use of knockout mutations, tagged inhibitor pull-down assays, and targeted identification methods.

In Vivo Photo-Cross-Linking to Study T3S Interactions Demonstrated Using the Yersinia pestis T3S System

Cross-linking of proteins is effective in determining protein-protein interactions. The use of photo-cross-linkers was developed to study protein interactions in several manners. One method involved the incorporation of photo-activatable cross-linking groups into chemically synthesized peptides. A second approach relies on incorporation of photo-activatable cross-linking groups into proteins using tRNAs with chemically bound photo-activatable amino acids with suppressor tRNAs translational systems to incorporate the tags into specific sites. A third system was made possible by the development of photoreactive amino acids that use the normal cellular tRNAs and aminoacyl tRNA synthetases. In this method, the third system is used to demonstrate its utility for the study of T3S system interactions. This method describes how two photo-activatable amino acids, photo-methionine and photo-leucine, that use the normal cellular machinery are incorporated into Yersinia pestis and used to study interactions in the T3S system. To demonstrate the system, the method was used to cross-link the T3S regulatory proteins LcrG and LcrV.

Analysis of Type III Secretion System Secreted Proteins

Secreted proteins of the T3SS vary from genus to genus. How secretion is induced in vitro also depends on the genus of bacteria. However, once those proteins are isolated the method for analyzing those proteins is largely the same. The following chapter outlines the specific induction of Yersinia secreted proteins and uniform analysis of those secreted proteins.

Introduction to Type III Secretion Systems

Type III secretion (T3S) systems are found in a large number of gram-negative bacteria where they function to manipulate the biology of infected hosts. Hosts targeted by T3S systems are widely distributed in nature and are represented by animals and plants. T3S systems are found in diverse genera of bacteria and they share a common core structure and function. Effector proteins are delivered by T3S systems into targeted host cells without prior secretion of the effectors into the environment. Instead, an assembled translocon structure functions to translocate effectors across eukaryotic cell membranes. In many cases, T3S systems are essential virulence factors and in some instances they promote symbiotic interactions.

Detection of Protein Interactions in T3S Systems Using Yeast Two-Hybrid Analysis

Two-hybrid systems, sometimes termed interaction traps, are genetic systems designed to find and analyze interactions between proteins. The most common systems are yeast based (commonly Saccharomyces cerevisae) and rely on the functional reconstitution of the GAL4 transcriptional activator. Reporter genes, such as the lacZ gene of Escherichia coli (encodes β-galactosidase), are placed under GAL4-dependent transcriptional control to provide quick and reliable detection of protein interactions. In this method the use of a yeast-based two-hybrid system is described to study protein interactions between components of type III secretion systems.

Mouse Immunization with Purified Needle Proteins from Type III Secretion Systems and the Characterization of the Immune Response to These Proteins

Many Gram-negative pathogens utilize a type III secretion (T3S) system to directly deliver effector molecules into host eukaryotic cells to manipulate cellular processes. These surface-exposed syringe-like structures are highly conserved, necessary for pathogenesis, and hence are therapeutic targets against a number of Gram-negative pathogens. Here we describe a protocol for using purified needle proteins to immunize mice, and subsequently, ways to characterize the immune response to immunization.

BscF from Bordetella pertussis provides advantageous adjuvant activity when paired with the acellular pertussis vaccine: enhanced Th1/Th17 pertussis-specific immune response

Incidence of pertussis, a severe respiratory disease caused by Bordetella pertussis, have been on the rise. This resurgence has been linked to antigenic divergence in circulating pertussis strains as well as waning or ineffective immunity induced by the current acellular pertussis (aP) vaccine. The current aP vaccine replaced a whole cell pertussis (wP) vaccine in the 1990s due to adverse events associated with the wP vaccine. Alum-absorbed aP vaccine has been shown to elicit a strong antibody response and considerable Th2 type CD4+ T cells. In contrast, wP vaccine promotes Th1/Th17 type cellular immunity and associated opsonizing antibodies presumably via its PAMPs. We have previously demonstrated that BscF, a B. pertussis needle protein, acts as a strong TLR agonist. Here we characterized the contribution of BscF to a laboratory prepared aP vaccine-induced response. aP + BscF resulted in statistically greater pertussis-specific antibody titers, compared to sham aP + PBS. BscF enhanced long-term aP-specific immunity, compared to either the alum or sham controls, as measured by increased numbers of central memory T cells. Moreover, the addition of BscF resulted in skewing the pertussis-specific immunity toward Th1 and Th17 responses, compared to the addition of alum or PBS which skewed pertussis-specific immunity away from Th1/Th17 responses. Mice immunized with aP + BscF demonstrated significantly reduced bacterial burden in their lungs 5 dpi. These findings suggest that BscF induced a strong Th1 and Th17 anti-pertussis response, potentially may provide protective BscF-specific immunity, and could be a novel additional component in the next generation aP vaccine.

Staphylococcal enterotoxin G and I: augmenting the T cell response to murine melanoma

Staphylococcal enterotoxins (SEs) have been shown to be effectual proteins which demonstrate anti-tumor activity. SEG and SEI, produced from the enterotoxin gene cluster (egc) of Staphylococcal aureus, activate T cells with Vβ specificity to elicit robust T cell proliferation, T helper cell 1 (TH1) and TH2 cytokine secretion, and nitric oxide dependent tumor lysis. Our data highlight the effects of SE stimulated T cells and the subsequent consequence on aggressive, metastatic cancer progression using B16-F10 murine melanoma model. Specifically, we explore the differences between major histocompatibility complex (MHC) and human leukocyte antigen (HLA) SE presentation to the T cells via the T cell receptor (TCR). Our data demonstrates increased survival of B16-F10 tumor bearing mice, C57BL/6 and DQ8 (HLA-DQA1*0301, HLA-DQB1*0302) transgenic mice, after irradiated B16-F10 vaccination and SE stimulation. Interestingly, SEG and SEI induce strong T cell proliferation yet do not induce neutralizing antibodies to the extent of classical SEs, SEA and SEB, nor induce autoimmune pathology. Our findings demonstrate that superantigen administration enhances lymphocytic tumor killing and suggest a potential role for SEG and SEI as potent immunotherapeutics for human cancer.

Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure

Andes virus (ANDV) and ANDV-like viruses are responsible for most hantavirus pulmonary syndrome (HPS) cases in South America. Recent studies in Chile indicate that passive transfer of convalescent human plasma shows promise as a possible treatment for HPS. Unfortunately, availability of convalescent plasma from survivors of this lethal disease is very limited. We are interested in exploring the concept of using DNA vaccine technology to produce antiviral biologics, including polyclonal neutralizing antibodies for use in humans. Geese produce IgY and an alternatively spliced form, IgYΔFc, that can be purified at high concentrations from egg yolks. IgY lacks the properties of mammalian Fc that make antibodies produced in horses, sheep, and rabbits reactogenic in humans. Geese were vaccinated with an ANDV DNA vaccine encoding the virus envelope glycoproteins. All geese developed high-titer neutralizing antibodies after the second vaccination, and maintained high-levels of neutralizing antibodies as measured by a pseudovirion neutralization assay (PsVNA) for over 1 year. A booster vaccination resulted in extraordinarily high levels of neutralizing antibodies (i.e., PsVNA80 titers >100,000). Analysis of IgY and IgYΔFc by epitope mapping show these antibodies to be highly reactive to specific amino acid sequences of ANDV envelope glycoproteins. We examined the protective efficacy of the goose-derived antibody in the hamster model of lethal HPS. α-ANDV immune sera, or IgY/IgYΔFc purified from eggs, were passively transferred to hamsters subcutaneously starting 5 days after an IM challenge with ANDV (25 LD50). Both immune sera, and egg-derived purified IgY/IgYΔFc, protected 8 of 8 and 7 of 8 hamsters, respectively. In contrast, all hamsters receiving IgY/IgYΔFc purified from normal geese (n=8), or no-treatment (n=8), developed lethal HPS. These findings demonstrate that the DNA vaccine/goose platform can be used to produce a candidate antiviral biological product capable of preventing a lethal disease when administered post-exposure.

(129.29)

We have previously reported that inbred B10.T(6R) mice are resistant to Yersinia pestis infection, compared to susceptible strains, e.g. Swiss Webster mice; the mean LD50's for B10.T(6R) females is 14000 CFU's, compared to Swiss Webster females, at 22 CFU's. Interestingly, B10.T(6R) mice demonstrated a more robust pro-inflammatory response early in infection, and a lesser anti-inflammatory response later on, when compared to susceptible Swiss Webster mice. Significantly higher levels of TNF-alpha were detected in B10.T(6R) on day 1 while TNF-alpha responses were delayed in Swiss Webster mice. Conversely, IL-10 levels were not changed in B10.T(6R) mice while IL-10 levels increased significantly in Swiss Webster mice. Yersinia outer membrane proteins (YOP) are translocated into the host cell's cytoplasm via a type three secretion system. After contact with a eukaryotic cell, YOPs then interact with cellular components to disrupt the host's immune response and induce the production of suppressive cytokines, e.g. IL-10. We postulate that the resistant B10.T(6R) strain of mice are able to overcome initial infection with Y. pestis through higher levels of pro-inflammatory cytokines and decreased levels of immune suppressive cytokines later in infection.

LcrG secretion is not required for blocking of Yops secretion in Yersinia pestis

Background

LcrG, a negative regulator of the Yersinia type III secretion apparatus has been shown to be primarily a cytoplasmic protein, but is secreted at least in Y. pestis. LcrG secretion has not been functionally analyzed and the relevance of LcrG secretion on LcrG function is unknown.

Results

An LcrG-GAL4AD chimera, originally constructed for two-hybrid analyses to analyze LcrG protein interactions, appeared to be not secreted but the LcrG-GAL4AD chimera retained the ability to regulate Yops secretion. This result led to further investigation to determine the significance of LcrG secretion on LcrG function. Additional analyses including deletion and substitution mutations of amino acids 2–6 in the N-terminus of LcrG were constructed to analyze LcrG secretion and LcrG's ability to control secretion. Some changes to the N-terminus of LcrG were found to not affect LcrG's secretion or LcrG's secretion-controlling activity. However, substitution of poly-isoleucine in the N-terminus of LcrG did eliminate LcrG secretion but did not affect LcrG's secretion controlling activity.

Conclusion

These results indicate that secretion of LcrG, while observable and T3SS mediated, is not relevant for LcrG's ability to control secretion.

Structure-function analysis of the C-terminal domain of LcrV from Yersinia pestis

LcrV, a multifunctional protein, acts as a positive regulator of effector protein secretion for the type III secretion system (T3SS) in Yersinia pestis by interaction with the negative regulator LcrG. In this study, LcrV was analyzed to identify regions required for LcrG interaction. Random-linker insertion mutagenesis, deletion analysis, and site-directed mutagenesis of hydrophobic amino acids between residues 290 and 311 allowed the isolation of an LcrV mutant (LcrV L291R F308R) defective for LcrG interaction. The new residues identified in LcrG interaction lie in helix 12 of LcrV; residues in helix 7 of LcrV are known to be involved in LcrG interaction. Helix 7 and helix 12 of LcrV interact to form an intramolecular coiled coil; these new results suggest that the intramolecular coiled coil in LcrV is required for LcrG interaction and activation of the T3SS.

Lethally-irradiated Yersinia pestis immunization protects against the plague: a novel vaccine candidate (47.23)

We provide evidence here that immunization with lethally γ-irradiated Yersinia pestis provides an effective and novel vaccine against the plague. Traditionally, neither chemical nor heat killing of bacteria has been successful in inducing an appropriate immune response to provide protection against further infection. It has been postulated, however, that inactivation via γ-irradiation would allow for retention of both adjuvant and antigenic components necessary for an effective vaccine. We hypothesize that, unlike many vaccines that induce predominately an antibody response, γ-irradiated whole bacteria will result in both a protective humoral and cellular immune response. Recent evidence that γ-irradiated Listeria monocytogenes protected mice from future exposure to L. monocytogenes supports this hypothesis.

Y. pestis, the cause of the plague, is endemic in much of the world. It creates a considerable health risk and is now also considered a putative agent for bioterrorism, although current vaccine candidates have potential pitfalls. Immunization with lethally γ-irradiated Y. pestis (600 kRads from a 137Ce source) provides significant protection against the plague in the absence of any additional stimulatory adjuvant in both inbred B10.T(6R) mice and out-bred Swiss Webster mice, LD50’s of greater than 106 CFUs in both strains, compared to 103 CFUs and 20 CFUs in sham immunized B10.T(6R) and Swiss Webster mice respectively. These data suggest both a new and effective vaccine for Y. pestis, as well as potential vaccines that have remained elusive for other bacteria.

Immunization of mice with YscF provides protection from Yersinia pestis infections

BACKGROUND

Yersinia pestis, the causative agent of plague, is a pathogen with a tremendous ability to cause harm and panic in populations. Due to the severity of plague and its potential for use as a bioweapon, better preventatives and therapeutics for plague are desirable. Subunit vaccines directed against the F1 capsular antigen and the V antigen (also known as LcrV) of Y. pestis are under development. However, these new vaccine formulations have some possible limitations. The F1 antigen is not required for full virulence of Y. pestis and LcrV has a demonstrated immunosuppressive effect. These limitations could damper the ability of F1/LcrV based vaccines to protect against F1-minus Y. pestis strains and could lead to a high rate of undesired side effects in vaccinated populations. For these reasons, the use of other antigens in a plague vaccine formulation may be advantageous.

RESULTS

Desired features in vaccine candidates would be antigens that are conserved, essential for virulence and accessible to circulating antibody. Several of the proteins required for the construction or function of the type III secretion system (TTSS) complex could be ideal contenders to meet the desired features of a vaccine candidate. Accordingly, the TTSS needle complex protein, YscF, was selected to investigate its potential as a protective antigen. In this study we describe the overexpression, purification and use of YscF as a protective antigen. YscF immunization triggers a robust antibody response to YscF and that antibody response is able to afford significant protection to immunized mice following challenge with Y. pestis. Additionally, evidence is presented that suggests antibody to YscF is likely not protective by blocking the activity of the TTSS.

CONCLUSION

In this study we investigated YscF, a surface-expressed protein of the Yersinia pestis type III secretion complex, as a protective antigen against experimental plague infection. Immunization of mice with YscF resulted in a high anti-YscF titer and provided protection against i.v. challenge with Y. pestis. This is the first report to our knowledge utilizing a conserved protein from the type III secretion complex of a gram-negative pathogen as a candidate for vaccine development.

Bile salts and fatty acids induce the expression of Escherichia coli AcrAB multidrug efflux pump through their interaction with Rob regulatory protein

AcrAB of Escherichia coli, an archetype among bacterial multidrug efflux pumps, exports an extremely wide range of substrates including solvents, dyes, detergents and antimicrobial agents. Its expression is regulated by three XylS/AraC family regulators, MarA, SoxS and Rob. Although MarA and SoxS regulation works by the alteration of their own expression levels, it was not known how Rob, which is constitutively expressed, exerts its regulatory action. We show here that the induction of the AcrAB efflux pump by decanoate and the more lipophilic unconjugated bile salts is mediated by Rob, and that the low-molecular-weight inducers specifically bind to the C-terminal, non-DNA-binding domain of Rob. Induction of Rob is not needed for induction of AcrAB, and we suggest that the inducers act by producing conformational alterations in pre-existing Rob, as was suggested recently (Rosner, Dangi, Gronenborn and Martin, J Bacteriol 184: 1407-1416, 2002). Decanoate and unconjugated bile salts, which are present in the normal habitat of E. coli, were further shown to make the bacteria more resistant to lipophilic antibiotics, at least in part because of the induction of the AcrAB efflux pump. Thus, it is likely that E. coli is protecting itself by the Rob-mediated upregulation of AcrAB against the harmful effects of bile salts and fatty acids in the intestinal tract.

Genome sequence of Yersinia pestis KIM

We present the complete genome sequence of Yersinia pestis KIM, the etiologic agent of bubonic and pneumonic plague. The strain KIM, biovar Mediaevalis, is associated with the second pandemic, including the Black Death. The 4.6-Mb genome encodes 4,198 open reading frames (ORFs). The origin, terminus, and most genes encoding DNA replication proteins are similar to those of Escherichia coli K-12. The KIM genome sequence was compared with that of Y. pestis CO92, biovar Orientalis, revealing homologous sequences but a remarkable amount of genome rearrangement for strains so closely related. The differences appear to result from multiple inversions of genome segments at insertion sequences, in a manner consistent with present knowledge of replication and recombination. There are few differences attributable to horizontal transfer. The KIM and E. coli K-12 genome proteins were also compared, exposing surprising amounts of locally colinear "backbone," or synteny, that is not discernible at the nucleotide level. Nearly 54% of KIM ORFs are significantly similar to K-12 proteins, with conserved housekeeping functions. However, a number of E. coli pathways and transport systems and at least one global regulator were not found, reflecting differences in lifestyle between them. In KIM-specific islands, new genes encode candidate pathogenicity proteins, including iron transport systems, putative adhesins, toxins, and fimbriae.

Interaction of the Yersinia pestis type III regulatory proteins LcrG and LcrV occurs at a hydrophobic interface

BACKGROUND

Secretion of anti-host proteins by Yersinia pestis via a type III mechanism is not constitutive. The process is tightly regulated and secretion occurs only after an appropriate signal is received. The interaction of LcrG and LcrV has been demonstrated to play a pivotal role in secretion control. Previous work has shown that when LcrG is incapable of interacting with LcrV, secretion of anti-host proteins is prevented. Therefore, an understanding of how LcrG interacts with LcrV is required to evaluate how this interaction regulates the type III secretion system of Y. pestis. Additionally, information about structure-function relationships within LcrG is necessary to fully understand the role of this key regulatory protein.

RESULTS

In this study we demonstrate that the N-terminus of LcrG is required for interaction with LcrV. The interaction likely occurs within a predicted amphipathic coiled-coil domain within LcrG. Our results demonstrate that the hydrophobic face of the putative helix is required for LcrV interaction. Additionally, we demonstrate that the LcrG homolog, PcrG, is incapable of blocking type III secretion in Y. pestis. A genetic selection was utilized to obtain a PcrG variant capable of blocking secretion. This PcrG variant allowed us to locate a region of LcrG involved in secretion blocking.

CONCLUSION

Our results demonstrate that LcrG interacts with LcrV via hydrophobic interactions located in the N-terminus of LcrG within a predicted coiled-coil motif. We also obtained preliminary evidence that the secretion blocking activity of LcrG is located between amino acids 39 and 53.

LcrG-LcrV interaction is required for control of Yops secretion in Yersinia pestis

Yersinia pestis expresses a set of plasmid-encoded virulence proteins called Yops and LcrV that are secreted and translocated into eukaryotic cells by a type III secretion system. LcrV is a multifunctional protein with antihost and positive regulatory effects on Yops secretion that forms a stable complex with a negative regulatory protein, LcrG. LcrG has been proposed to block the secretion apparatus (Ysc) from the cytoplasmic face of the inner membrane under nonpermissive conditions for Yops secretion, when levels of LcrV in the cell are low. A model has been proposed to describe secretion control based on the relative levels of LcrG and LcrV in the bacterial cytoplasm. This model proposes that under secretion-permissive conditions, levels of LcrV are increased relative to levels of LcrG, so that the excess LcrV titrates LcrG away from the Ysc, allowing secretion of Yops to occur. To further test this model, a mutant LcrG protein that could no longer interact with LcrV was created. Expression of this LcrG variant blocked secretion of Yops and LcrV under secretion permissive conditions in vitro and in a tissue culture model. These results agree with the previously described secretion-blocking activity of LcrG and demonstrate that the interaction of LcrV with LcrG is necessary for controlling Yops secretion.

Virulence role of V antigen of Yersinia pestis at the bacterial surface

Yersinia pestis, the etiologic agent of plague, secretes a set of environmentally regulated, plasmid pCD1-encoded virulence proteins termed Yops and V antigen (LcrV) by a type III secretion mechanism (Ysc). LcrV is a multifunctional protein that has been shown to act at the level of secretion control by binding the Ysc inner-gate protein LcrG and to modulate the host immune response by altering cytokine production. LcrV also is essential for the unidirectional targeting of Yops to the cytosol of infected eukaryotic cells. In this study, we constructed an in-frame deletion within lcrG (DeltalcrG3) to further analyze the requirement of LcrV in Yop targeting. We confirmed the essentiality of LcrV and found that LcrG may have a facilitative role, perhaps by promoting efficient secretion of LcrV. We also constructed mutants of lcrV expressing LcrV truncated at the N or C terminus. Both the N and C termini of LcrV were required for the secretion of LcrV into the medium and targeting of Yops. LcrV was detected in punctate zones on the surface of fixed Y. pestis by laser-scanning confocal microscopy, and this localization required a functional Ysc. However, the truncated LcrV proteins were not found on the bacterial surface. Finally, we tested the ability of LcrV-specific Fab antibody fragments or full-length antibody to interfere with Yop targeting and found no interference, even though this antibody protects mice against plague. These results indicate that LcrV may function in Yop targeting at the extracellular surface of yersiniae and that the protective efficacy of LcrV-specific antibodies can be manifested without blocking Yop targeting.

The V antigen of Yersinia pestis regulates Yop vectorial targeting as well as Yop secretion through effects on YopB and LcrG

Yersinia pestis expresses a set of secreted proteins called Yops and the bifunctional LcrV, which has both regulatory and antihost functions. Yops and LcrV expression and the activity of the type III mechanism for their secretion are coordinately regulated by environmental signals such as Ca2+ concentration and eukaryotic cell contact. In vitro, Yops and LcrV are secreted into the culture medium in the absence of Ca2+ as part of the low-Ca2+ response (LCR). The LCR is induced in a tissue culture model by contact with eukaryotic cells that results in Yop translocation into cells and subsequent cytotoxicity. The secretion mechanism is believed to indirectly regulate expression of lcrV and yop operons by controlling the intracellular concentration of a secreted negative regulator. LcrG, a secretion-regulatory protein, is thought to block secretion of Yops and LcrV, possibly at the inner face of the inner membrane. A recent model proposes that when the LCR is induced, the increased expression of LcrV yields an excess of LcrV relative to LcrG, and this is sufficient for LcrV to bind LcrG and unblock secretion. To test this LcrG titration model, LcrG and LcrV were expressed alone or together in a newly constructed lcrG deletion strain, a delta lcrG2 mutant, of Y. pestis that produces low levels of LcrV and constitutively expresses and secretes Yops. Overexpression of LcrG in this mutant background was able to block secretion and depress expression of Yops in the presence of Ca2+ and to dramatically decrease Yop expression and secretion in growth medium lacking Ca2+. Overexpression of both LcrG and LcrV in the delta lcrG2 strain restored wild-type levels of Yop expression and Ca2+ control of Yop secretion. Surprisingly, when HeLa cells were infected with the delta lcrG2 strain, no cytotoxicity was apparent and translocation of Yops was abolished. This correlated with an altered distribution of YopB as measured by accessibility to trypsin. These effects were not due to the absence of LcrG, because they were alleviated by restoration of LcrV expression and secretion alone. LcrV itself was found to enter HeLa cells in a nonpolarized manner. These studies supported the LcrG titration model of LcrV's regulatory effect at the level of Yop secretion and revealed a further role of LcrV in the deployment of YopB, which in turn is essential for the vectorial translocation of Yops into eukaryotic cells.

Yersinia pestis LcrV forms a stable complex with LcrG and may have a secretion-related regulatory role in the low-Ca2+ response

Yersinia pestis contains a virulence plasmid, pCD1, that encodes many virulence-associated traits, such as the Yops (Yersinia outer proteins) and the bifunctional LcrV, which has both regulatory and antihost functions. In addition to LcrV and the Yops, pCD1 encodes a type III secretion system that is responsible for Yop and LcrV secretion. The Yop-LcrV secretion mechanism is believed to regulate transcription of lcrV and yop operons indirectly by controlling the intracellular concentration of a secreted repressor. The activity of the secretion mechanism and consequently the expression of LcrV and Yops are negatively regulated in response to environmental conditions such as Ca2+ concentration by LcrE and, additionally, by LcrG, both of which have been proposed to block the secretion mechanism. This block is removed by the absence of Ca2+ or by contact with eukaryotic cells, and some Yops are then translocated into the cells. Regulation of LcrV and Yop expression also is positively affected by LcrV. Previously, LcrG was shown to be secreted from bacterial cells when the growth medium lacks added Ca2+, although most of the LcrG remains cell associated. In the present study, we showed that the cell-associated LcrG is cytoplasmically localized. We demonstrated that LcrG interacts with LcrV to form a heterodimeric complex by using chemical cross-linking and copurification of LcrG and LcrV. Additionally, we found that small amounts of LcrV and YopE can be detected in periplasmic fractions isolated by cold osmotic shock and spheroplast formation, indicating that their secretion pathway is accessible to the periplasm or to these procedures for obtaining periplasmic fractions. We propose that the cytoplasmically localized LcrG blocks the Yop secretion apparatus from the cytoplasmic side and that LcrV is required to remove the LcrG secretion block to yield full induction of Yop and LcrV secretion and expression.